ATYR:NASDAQ
aTyr Pharma Inc
$0.51
arrow_upward
+2.58%(+0.013) 1D
$0.52
arrow_upward
+1.99% (+0.010)bedtimeAfter hours
Closed: Jun 4, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ATYR...
Open
$0.51
High
$0.54
Low
$0.51
Mkt. cap
50.31M
Avg. vol.
3.51M
Volume
1.47M
52-wk high
$7.29
52-wk low
$0.40
EPS
-$0.73
Beta
0.55
Shares outstanding
98.05M
No. of employees
59
Open
$0.51
High
$0.54
Low
$0.51
Mkt. cap
50.31M
Avg. vol.
3.51M
Volume
1.47M
52-wk high
$7.29
52-wk low
$0.40
EPS
-$0.73
Beta
0.55
Shares outstanding
98.05M
No. of employees
59
Analyst outlook
Analyst Ratings
Based on 6 analysts giving stock ratings to ATYR in the past 3 months
Buy
Buy
2
Hold
4
Sell
0
12 month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ATYR in the last 3 months.
Highest
Current $0.51
$20.00 (+3,798.64%)
Average
$6.38 (+1,143.66%)
Lowest
$1.00 (+94.93%)
News stories
From sources across the web
Profile
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
About aTyr Pharma Inc
AI content may include mistakes. Learn more